Revvity (RVTY)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$130.22-0.31%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · RVTY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 16.8% |
| Our one-year growth estimate | diamond | 2.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 14.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers
RVTY — divestiture
Dated 2026-08-04
Other Events Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of the Company and its Subsidiaries based upon historical financial information after giving effect to the probable sale of substantially all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a definitive agreement signed on July 31, 202…
Why it matters: Management noted encouraging signs of demand. This could indicate a positive trend for revenue growth.
Supportive ifManagement will report more customer orders or contracts in the next earnings call.
Worry ifManagement will say there is less customer demand or that orders are canceled.
Why it matters: A miss raises worries about Revvity's growth and market position.
Worry ifQ2 2026 earnings report shows revenue below $740 million.
Less concerning ifQ2 2026 earnings report shows revenue above $740 million.
Why it matters: Lower organic growth shows market problems. This can hurt investor confidence.
Worry ifOrganic revenue growth was below 2% for 2026.
Less concerning ifOrganic revenue growth meets or exceeds 3% for 2026.
Why it matters: This guidance shows what management expects for making money and growth.
Watch forAdjusted EPS reported within the range of $5.35-$5.45 in future earnings.
Also watch forAdjusted EPS is expected to be below $5.20 in future earnings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $362 loss on $10,000 · 3.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,009 loss on $10,000 · 30.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Diagnostics segment is important for total revenue. Trends here can show overall business health.
Watch forDiagnostics segment revenue growth reported at 8% or higher in the next earnings report.
Also watch forDiagnostics segment revenue growth is expected to be below 4% in the next earnings report.
Why it matters: Closing this deal will remove a business that contributed 6% of revenue. It may improve focus and profitability.
Supportive ifThe sale will close by the end of 2027. It needs regulatory approvals first.
Worry ifThe divestiture is delayed beyond 2027 or fails to close.
Why it matters: Hitting this growth target shows strong demand. It also shows good management performance.
Supportive ifQ3 pro forma organic revenue growth reported at 4% or higher.
Worry ifQ3 pro forma organic revenue growth reported below 3%.
Why it matters: Meeting or beating this EPS target shows strong profits. It also shows good cost control.
Supportive ifQ3 pro forma adjusted EPS reported at $5.30 or higher.
Worry ifQ3 pro forma adjusted EPS reported below $5.20.
Why it matters: Changes in revenue guidance may show market shifts. They can also show operational problems.
Watch forManagement increases revenue guidance for 2026. It is now above $2.86 billion.
Also watch forManagement decreases revenue guidance for 2026. It is now below $2.81 billion.